Improved results after lung transplantation-analysis of factors

Swiss Medical Weekly

Volumn 131, Issue 17-18, 2001, Pages 238-245

  Speich, Rudolf ^a   Boehler, A ^a   Zalunardo, M P ^a   Stocker, R ^a   Russi, E W ^a   Weder, W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute rejection; Bronchiolitis obliterans; Cytomegalovirus; Ganciclovir; Immunosuppression; Lung transplantation; Mycophenolate mofetil; Transbronchial biopsy

Indexed keywords

GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION;

EID: 0035810551     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081-91.
2. Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997;155:789-818.
3. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report - 2000. J Heart Lung Transplant 2000;19:909-31.
4. Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998;114: 1411-26.
5. Paradis I, Yousem S, Grifith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med 1993;14:751-63.
6. International Society for Heart and Lung Transplantation. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993;12:713-6.
7. Bando K, Paradis IL, Komatsu K, Konishi H, Matsushima M, Keena RJ, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995;109:49-57.
8. Heng H, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998;17:1255-63.
9. Reichenspurner H, Girgis RE, Robbins RC, Yun KL, Nitschke M, Berry GJ, et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1996;62:1467-72.
10. Scott JP, Higenbottam TW, Sharples L, Clelland CA, Smyth RL, Steuart S, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991;51: 813-7.
11. Sharples LD, Tamm M, McNeil K, Higenbottam TW, Stewart S, Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation - early risk factors. Transplantation 1996;61:560-6.
12. Higenbottam T, Stewart S, Penketh A, Wallwork J. Transbronchial biopsy for the diagnosis of rejection in heart-lung transplant patients. Transplantation 1988;46:532-9.
13. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper JD. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992;102:1049-54.
14. Boehler A, Vogt P, Zollinger A, Weder W, Speich R. Prospective study of the value of transbronchial lung biopsy after lung transplantation. Eur Respir J 1996;9:658-62.
15. Speich R, Boehler A, Thurnheer R, Weder W. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans. Importance of dosage. Transplantation 1997;64: 533-5.
16. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999;67:315-20.
17. Kaiser LR, Pasque MK, Trulock EP, Low DE, Dresler CM, Cooper JD. Bilateral sequential lung transplantation: the procedure of choice for double-lung replacement. Ann Thorac Surg 1991;52:438-45.
18. Patterson GA, Cooper JD, Goldman B, Weisel RD, Pearson FJ, Waters PF, et al. Technique of successful clinical double-lung transplantation. Ann Thorac Surg 1988;45:626-33.
19. Toronto Lung Transplant Group. Unilateral lung transplantation tor pulmonary fibrosis. N Engl J Med 1986;314:1140-5.
20. Schmid RA, Boehler A, Speich R, Frey HR, Russi EW, Weder W. Bronchial anastomotic complications following lung transplantation: still a major cause of morbidity? Eur Respir J 1997; 10:2872-5.
21. Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dal l'Amico R, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998;339:1744-51.
22. Yousem SA, Berry, GJ. Cagle PT, Chamberlain D, Husain AN, Hruban RH, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996;15:1-15.
23. O'Hair DP, Cantu E, McGregor C, Jorgensen B, Gerow-Smith R, Galantowicz ME, et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant 1998;17:864-8.
24. Ross DJ, Waters PF, Levine M, Kramer M, Ruzevich S, Kass RM, Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 1998;17:768-74.
25. Zuckermann A, Klepetko W, Birsan T, Taghavi S, Artemiou O, Wisser W, et al. Comparison between mycophenolate mofetiland azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999;18:432-40.
26. Duncan SR, Paradis IL, Yousem SA, Similo SL, Grgurich WF, Williams PA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146:1419-25.
27. Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JA, Rabinowich II, et al. Cytomegalovirus serologic status and post-operative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991;51:433-8.
28. Duncari SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994;150:146-52.
29. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15:881-7.
30. Chaparro C, Scavuzzo M, Winton T, Keshavjee S, Kesten S. Status of lung transplant recipients surviving beyond five years. J Heart Lung Transplant 1997;16:511-6.
31. Meyers BF, Lynch J, Trulock EP, Guthrie TJ, Cooper JD, Patterson GA. Lung transplantation: a decade of experience. Ann Surg 1999;230:362-70.